Attention! Your ePaper is waiting for publication!
By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 million ePaper readers on YUMPU.
This will ensure high visibility and many readers!
![illustration](https://assets.yumpu.com/release/9AmF671O0aR9zQ4/v5/img/account/document_privacy_modal/step1.png)
Your ePaper is now published and live on YUMPU!
You can find your publication here:
Share your interactive ePaper on all platforms and on your website with our embed function
![illustration](https://assets.yumpu.com/release/9AmF671O0aR9zQ4/v5/img/account/document_privacy_modal/step2.png)
Air Quality Criteria for Lead Volume II of II - (NEPIS)(EPA) - US ...
Air Quality Criteria for Lead Volume II of II - (NEPIS)(EPA) - US ...
Air Quality Criteria for Lead Volume II of II - (NEPIS)(EPA) - US ...
- TAGS
- criteria
- volume
- nepis.epa.gov
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ANNEX TABLES AX5-5<br />
AX5-60
AX5-59 Citation Taupeau et al. (2001) Tchernitchin et al. (1998a) Tchernitchin et al. (1998b) Table AX5-4.3 (cont’d). Effect <strong>of</strong> <strong>Lead</strong> on Reproduction and Development in Mammals Effects on Females Species/ Strain/Age Mouse/C57blxC BA, 8 wks old Rat/Sprague- Dawley, 14 days old Rat/Sprague- Dawley, 20 or 21 days old Wide (1985) Mouse/NMRI, 10 wks old Wide and D'Argy (1986) Wiebe and Barr (1988) Wiebe et al. (1988) Yu et al. (1996) Mouse/NMRI, adult Rat/Sprague- Dawley, adult Rat/Sprague- Dawley, adult Rat/Sprague- Dawley, adult Dose/Route/ Form/Duration Endpoint 10 mg/kg-d Pb nitrate via i.v. <strong>for</strong> 15 days 172 µg/g bw Pb from day 14 every 2nd day until day 20 (75 mg/g bw) Pb via i.v. one time exposure at 1 or 24 be<strong>for</strong>e hormone stimulation 20 µg/dL/g bw Pb chloride via i.v. single exposure on days 8, 12, or 16 after mating 20 µg/g bw by i.v. single injection on GD 8 20 or 200 ppm Pb chloride in drinking water; 3 exposure durations; prior to mating through weaning, GD 7 to weaning, PND 21 to PND 35 20 or 200 ppm Pb chloride in drinking water; 4 exposure durations; prior to mating through weaning, GD 7 to weaning, PND 21 to PND 35, prior to mating only Neonatal and lactational exposure to 0.3% Pb acetate in drinking water (PND 30) Low Pb concentration in the ovary caused dysfunction <strong>of</strong> folliculogenesis, with fewer primordial follicles and an increase in atretic antral follicles. Pb inhibits estrogen-induced uterine eosinophilia at 6 and 24 hr after treatment; Pb also inhibits estrogen-induced edema in deep and superficial endometrial stoma at 24 hr but not 6 hr after treatment; myometrial hypertrophy is inhibited under the effect <strong>of</strong> exposure at 24 hr <strong>of</strong> treatment. Enhanced some parameters <strong>of</strong> estrogen stimulation and inhibited other estrogenic responses; interaction with responses to estrogen was different depending on whether Pb pretreatment was 1 or 24 hr be<strong>for</strong>e hormone stimulation; estrogenic responses mostly affected were uterine eosinophilia, endometrial edema, uterine liminal epithelial, hypertrophy, and mitosis in various, but not all, uterine cell types, in some cell types, estrogen-induced mitotic response developed earlier under the effect <strong>of</strong> Pb exposure. Litter size and fetal survival varied significantly; small litters and increased numbers <strong>of</strong> fetal deaths were observed in mice exposed to Pb on day 8 <strong>of</strong> intrauterine life; live fetuses were normal with respect to weight and morphological appearance; ovarian follicle counts revealed a significantly smaller number <strong>of</strong> primordial follicles in the latter group, it suggested that the exposure to Pb at a time <strong>of</strong> early organogenesis caused the observed fertility decrease by interfering with the development <strong>of</strong> the female germ cells. Primordial germ cells showed a normal body distribution but were significantly fewer at all four stages compared with those <strong>of</strong> control embryos <strong>of</strong> corresponding age; Pb had interfered with the production or activity <strong>of</strong> alkaline phosphatase. Treatment with Pb prior to mating resulted in significant increase in E2-receptor affinity in 21-day old <strong>of</strong>fspring without a change in E2 receptor number; treatment from day 7 <strong>of</strong> pregnancy until weaning <strong>of</strong> the pups resulted in ~35% decrease in E2 receptors per mg uterine protein when these <strong>of</strong>fspring reached 150 days <strong>of</strong> age; Pb treatment from 21–35 days old or until 150 days resulted in a significant decrease in uterine E2 receptor number at 35 and 150 day, respectively. Exposure to Pb did not affect tissue weights but did cause a significant decrease in gonadotropin-receptor binding in the pre-pubertal, pubertal, and adult females; conversion <strong>of</strong> progesterone to androstenedione and dihydrotestosterone was significantly decreased in 21-day old rats and in 150-day old females; significantly increased conversion to the 5-alpha-reduced steroids, normally high during puberty. Neonatal exposure to Pb decreased cold-water swimming endurance (a standard test <strong>for</strong> stress endurance); delayed onset <strong>of</strong> puberty in males and female <strong>of</strong>fspring, which was exacerbated by swimming stress. Blood <strong>Lead</strong> Concentration (PbB) PbB not reported PbB 47 µg/dL PbB not reported PbB not reported PbB not reported PbB likely 4.0 ± 1.4 to 6.6 ± 2.3 µg/dL (similar design as Wiebe et al. (1988) PbB range 4.0 ± 1.4 to 6.6 ± 2.3 µg/dL PbB 70 µg/dL *Not including effects on the nervous or immune systems. † Candidate key study. E2, estradiol; FSH, follicle stimulating hormone; GD, gestational day; GnRH, gonadotropin releasing hormone; HET, Binghamton Heterogeneous Stock; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; LH, luteinizing hormone; NOS, not otherwise specified; PbB, blood lead concentration; PND, post-natal day; p.o., per os (oral administration); SRIF, somatostatin; StAR, steroidogenic acute regulatory protein.
ANNEX TABLES AX5-5 AX5-60
- Page 1 and 2:
October 2006 EPA/600/R-05/144bF Air
- Page 3 and 4:
PREFACE National Ambient Air Qualit
- Page 5 and 6:
NCEA acknowledges the valuable cont
- Page 7 and 8:
Table of Contents Page PREFACE ....
- Page 9 and 10:
Authors, Contributors, and Reviewer
- Page 11 and 12:
Contributors and Reviewers (cont’
- Page 13 and 14:
Contributors and Reviewers (cont’
- Page 15 and 16:
Executive Direction U.S. Environmen
- Page 17 and 18:
Chair U.S. Environmental Protection
- Page 19 and 20:
Abbreviations and Acronyms αFGF α
- Page 21 and 22:
BLL blood lead level BLM biotic lig
- Page 23 and 24:
CRI chronic renal insufficiency CSF
- Page 25 and 26:
EPT macroinvertebrates from the Eph
- Page 27 and 28:
GRP78 glucose-regulated protein 78
- Page 29 and 30:
KABC Kaufman Assessment Battery for
- Page 31 and 32:
NADP nicotinamide adenine dinucleot
- Page 33 and 34:
Pb(Ac)2 lead acetate PbB blood lead
- Page 35 and 36:
RR RT RSEM RSUC RT ∑SEM SA7 SAB S
- Page 37 and 38:
TGF transforming growth factor TH t
- Page 39 and 40:
AX4. CHAPTER 4 ANNEX ANNEX TABLES A
- Page 41 and 42:
AX4-3 Table AX4-1 (cont’d). Analy
- Page 43 and 44:
AX4-5 Table AX4-2 (cont’d). Summa
- Page 45 and 46:
AX4-7 Table AX4-3. Bone Lead Measur
- Page 47 and 48:
AX4-9 Reference, Study Location, an
- Page 49 and 50:
AX4-11 Table AX4-4 (cont’d). Bone
- Page 51 and 52:
AX4-13 Table AX4-5 (cont’d). Bone
- Page 53 and 54:
AX4-15 Table AX4-5 (cont’d). Bone
- Page 55 and 56:
AX4-17 Table AX4-5 (cont’d). Bone
- Page 57 and 58:
AX4-19 Reference, Study Location, a
- Page 59 and 60:
AX4-21 Reference, Study Location, a
- Page 61 and 62:
AX4-23 Reference, Study Location, a
- Page 63 and 64:
AX4-25 Reference, Study Location, a
- Page 65 and 66:
AX4-27 Reference, Study Location, a
- Page 67 and 68:
AX4-29 Reference, Study Location, a
- Page 69 and 70:
AX4-31 Table AX4-8 (cont’d). Bone
- Page 71 and 72:
AX4-33 Table AX4-8 (cont’d). Bone
- Page 73 and 74:
AX4-35 Table AX4-8 (cont’d). Bone
- Page 75 and 76:
AX4-37 Table AX4-9 (cont’d). Lead
- Page 77 and 78:
AX4-39 Table AX4-11. Summary of Sel
- Page 79 and 80:
AX4-41 Table AX4-11 (cont’d). Sum
- Page 81 and 82:
AX-43 Table AX4-12 (cont’d). Summ
- Page 83 and 84:
Barltrop, D.; Meek, F. (1979) Effec
- Page 85 and 86:
Carroll, R. J.; Galindo, C. D. (199
- Page 87 and 88:
Flegal, A. R.; Smith, D. R. (1995)
- Page 89 and 90:
Gulson, B.; Mizon, K.; Smith, H.; E
- Page 91 and 92:
Khoury, G. A.; Diamond, G. L. (2003
- Page 93 and 94:
Morgan, W. D.; Ryde, S. J.; Jones,
- Page 95 and 96:
Pounds, J. G.; Leggett, R. W. (1998
- Page 97 and 98:
Skerfving, S. (1988) Biological mon
- Page 99 and 100:
U.S. Environmental Protection Agenc
- Page 101 and 102:
Air Quality Criteria for Lead Volum
- Page 103 and 104:
AQCD/Addendum and 1990 Supplement,
- Page 105 and 106:
Air Quality Criteria for Lead (Seco
- Page 107 and 108:
List of Tables AX4-1 Analytical Met
- Page 109 and 110:
List of Tables (cont’d) AX5-6.3 G
- Page 111 and 112:
List of Tables (cont’d) AX5-9.3 S
- Page 113 and 114:
Principal Authors (cont’d) Author
- Page 115 and 116:
Principal Authors Authors, Contribu
- Page 117 and 118:
Principle Authors (cont’d) Author
- Page 119 and 120:
Technical Support Staff U.S. Enviro
- Page 121 and 122:
Members (cont’d) U.S. Environment
- Page 123 and 124:
ANP atrial natriuretic peptide AP a
- Page 125 and 126:
CCE Coordination Center for Effects
- Page 127 and 128:
DR drinking water DSA delayed spati
- Page 129 and 130:
FTII Fagan Test of Infant Intellige
- Page 131 and 132:
H3PO4 phosphoric acid HPRT hypoxant
- Page 133 and 134:
MATC maximum acceptable threshold c
- Page 135 and 136:
NOS nitric oxide synthase; not othe
- Page 137 and 138:
PPVT-R Peabody Picture Vocabulary T
- Page 139 and 140:
SOPR sperm-oocyte penetration rate
- Page 141 and 142:
vit C vitamin C vit E vitamin E VMA
- Page 143 and 144:
AX5-2 Table AX5-2.1. Effect of Lead
- Page 145 and 146:
AX5-4 Table AX5-2.1 (cont’d). Eff
- Page 147 and 148:
AX5-6 Table AX5-2.2. Lead, Erythroc
- Page 149 and 150: AX5-8 Table AX5-2.2 (cont’d). Lea
- Page 151 and 152: AX5-10 Table AX5-2.4. Lead Effects
- Page 153 and 154: AX5-12 Table AX5-2.5. Lead Interact
- Page 155 and 156: AX5-14 Table AX5-2.7. Lead, Erythro
- Page 157 and 158: AX5-16 Subject Exposure Protocol Ra
- Page 159 and 160: AX5-18 Subject Exposure Protocol Ra
- Page 161 and 162: AX5-20 Subject Exposure Protocol Ra
- Page 163 and 164: AX5-22 Subject Rat, female, 22 wks
- Page 165 and 166: AX5-24 Subject Rat, F344, male Expo
- Page 167 and 168: AX5-26 Subject Monkey, cynomolgus,
- Page 169 and 170: AX5-28 Subject Rat, SD, male, PND 6
- Page 171 and 172: AX5-30 Subject Monkey, cynomolgus,
- Page 173 and 174: AX5-32 Subject Exposure Protocol Ta
- Page 175 and 176: AX5-34 Table AX5-3.6 (cont’d). Ke
- Page 177 and 178: AX5-36 Table AX5-3.6 (cont’d). Ke
- Page 179 and 180: AX5-38 Citation Al-Hakkak et al. (1
- Page 181 and 182: AX5-40 Citation Fox et al. (1997)
- Page 183 and 184: AX5-42 Citation Pinon- Lataillade e
- Page 185 and 186: AX5-44 Citation Wiebe et al. (1998)
- Page 187 and 188: AX5-46 Citation Chowdhuri et al. (2
- Page 189 and 190: AX5-48 Citation Graca et al. (2004)
- Page 191 and 192: AX5-50 Citation Marchlewicz et al.
- Page 193 and 194: AX5-52 Table AX5-4.2 (cont’d). Ef
- Page 195 and 196: AX5-54 Citation Sokol et al. (1985)
- Page 197 and 198: AX5-56 Citation Table AX5-4.3 (cont
- Page 199: AX5-58 Citation Priya et al. (2004)
- Page 203 and 204: AX5-62 Table AX5-5.1 (cont’d). In
- Page 205 and 206: AX5-64 Table AX5-5.1 (cont’d). In
- Page 207 and 208: AX5-66 Reference Watts et al. (1995
- Page 209 and 210: AX5-68 Reference Lai et al. (2002)
- Page 211 and 212: AX5-70 Reference Shelkovnikov and G
- Page 213 and 214: AX5-72 Reference Fujiwara and Kaji
- Page 215 and 216: AX5-74 Reference Fugiwara et al. (1
- Page 217 and 218: AX5-76 Table AX5-6.1. Genotoxic/Car
- Page 219 and 220: AX5-78 Table AX5-6.2. Genotoxic/Car
- Page 221 and 222: AX5-80 Table AX5-6.3 (cont’d). Ge
- Page 223 and 224: AX5-82 Table AX5-6.4 (cont’d). Ge
- Page 225 and 226: AX5-84 Table AX5-6.4 (cont’d). Ge
- Page 227 and 228: AX5-86 Compound Table AX5-6.6. Geno
- Page 229 and 230: AX5-88 Compound Table AX5-6.7. Geno
- Page 231 and 232: AX5-90 Table AX5-6.8. Genotoxic/Car
- Page 233 and 234: AX5-92 Compound Table AX5-6.9. Geno
- Page 235 and 236: AX5-94 Table AX5-6.9 (cont’d). Ge
- Page 237 and 238: AX5-96 Table AX5-6.10 (cont’d). G
- Page 239 and 240: AX5-98 Table AX5-6.12. Genotoxic/Ca
- Page 241 and 242: AX5-100 Table AX5-6.14. Genotoxic/C
- Page 243 and 244: AX5-102 Compound Table AX5-6.16. Ge
- Page 245 and 246: AX5-104 Table AX5-6.18. Genotoxic/C
- Page 247 and 248: AX5-106 Table AX5-6.18 (cont’d).
- Page 249 and 250: AX5-108 Table AX5-6.19 (cont’d).
- Page 251 and 252:
AX5-110 Compound Assay (Concentrati
- Page 253 and 254:
AX5-112 Table AX5-7.1. Light Micros
- Page 255 and 256:
AX5-114 Table AX5-7.2. Lead and Fre
- Page 257 and 258:
AX5-116 Table AX5-7.2 (cont’d). L
- Page 259 and 260:
AX5-118 Table AX5-7.4. Effect of Ch
- Page 261 and 262:
AX5-120 Table AX5-7.5 (cont’d). E
- Page 263 and 264:
AX5-122 Table AX5-8.1. Bone Growth
- Page 265 and 266:
AX5-124 Table AX5-8.1 (cont’d). B
- Page 267 and 268:
AX5-126 Table AX5-8.2. Regulation o
- Page 269 and 270:
AX5-128 Table AX5-8.2 (cont’d). R
- Page 271 and 272:
AX5-130 Table AX5-8.3 (cont’d). B
- Page 273 and 274:
AX5-132 Table AX5-8.3 (cont’d). B
- Page 275 and 276:
AX5-134 Table AX5-8.3 (cont’d). B
- Page 277 and 278:
AX5-136 Table AX5-8.4. Bone Lead as
- Page 279 and 280:
AX5-138 Table AX5-8.4 (cont’d). B
- Page 281 and 282:
AX5-140 Table AX5-8.4 (cont’d). B
- Page 283 and 284:
AX5-142 Table AX5-8.5. Uptake of Le
- Page 285 and 286:
AX5-144 Table AX5-8.7. Effects of L
- Page 287 and 288:
ANNEX TABLES AX5-9 AX5-146
- Page 289 and 290:
AX5-148 Nature of Exposure Table AX
- Page 291 and 292:
AX5-150 Table AX5-9.2. Effect of Le
- Page 293 and 294:
AX5-152 Species Strain/Gender Age M
- Page 295 and 296:
AX5-154 Table AX5-9.5 (cont’d). E
- Page 297 and 298:
ANNEX TABLES AX5-10 AX5-156
- Page 299 and 300:
AX5-158 Table AX5-10.1 (cont’d).
- Page 301 and 302:
AX5-160 Table AX5-10.1 (cont’d).
- Page 303 and 304:
AX5-162 Table AX5-10.2. Biochemical
- Page 305 and 306:
AX5-164 Table AX5-10.2 (cont’d).
- Page 307 and 308:
AX5-166 Table AX5-10.4. Lead, Oxida
- Page 309 and 310:
AX5-168 Table AX5-10.4 (cont’d).
- Page 311 and 312:
AX5-170 Table AX5-10.4 (cont’d).
- Page 313 and 314:
AX5-172 Table AX5-10.5 (cont’d).
- Page 315 and 316:
AX5-174 Table AX5-10.5 (cont’d).
- Page 317 and 318:
AX5-176 Table AX5-10.5 (cont’d).
- Page 319 and 320:
AX5-178 Table AX5-10.6 (cont’d).
- Page 321 and 322:
AX5-180 Table AX5-10.7. Lead and In
- Page 323 and 324:
AX5-182 Table AX5-10.8 (cont’d).
- Page 325 and 326:
AX5-184 Table AX5-10.9. Lead, Calci
- Page 327 and 328:
ANNEX TABLES AX5-11 AX5-186
- Page 329 and 330:
AX5-188 Source Organ Species Table
- Page 331 and 332:
REFERENCES Abdollahi, M.; Dehpour,
- Page 333 and 334:
Bataineh, H.; Al-Hamood, M. H.; Elb
- Page 335 and 336:
Buchet, J.-P.; Roels, H. E.; Huberm
- Page 337 and 338:
Cline, H. T.; Witte, S.; Jones, K.
- Page 339 and 340:
Cory-Slechta, D. A.; McCoy, L.; Ric
- Page 341 and 342:
children's health: immune and respi
- Page 343 and 344:
Ferguson, C.; Kern, M.; Audesirk, G
- Page 345 and 346:
Fullmer, C. S. (1991) Intestinal ca
- Page 347 and 348:
Goyer, R. A.; Leonard, D. L.; Moore
- Page 349 and 350:
Hengstler, J. G.; Bolm-Audorff, U.;
- Page 351 and 352:
Jacquet, P.; Leonard, A.; Gerber, G
- Page 353 and 354:
Kim, K. A.; Chakraborti, T.; Goldst
- Page 355 and 356:
Laughlin, N. K.; Bowman, R. E.; Fra
- Page 357 and 358:
Maldonado-Vega, M.; Cerbón-Solórz
- Page 359 and 360:
Moorman, W. J.; Skaggs, S. R.; Clar
- Page 361 and 362:
O'Flaherty, E. J.; Inskip, M. J.; F
- Page 363 and 364:
Price, R. G.; Taylor, S. A.; Chiver
- Page 365 and 366:
Rodamilans, M.; Mtz.-Osaba, M. J.;
- Page 367 and 368:
Schlipkoter, H.-W.; Frieler, L. (19
- Page 369 and 370:
Skoczyńska, A.; Smolik, R.; Jeleń
- Page 371 and 372:
Tavakoli-Nezhad, M.; Pitts, D. K. (
- Page 373 and 374:
Valentino, M.; Governa, M.; Marchis
- Page 375 and 376:
Wetmur, J. G.; Lehnert, G.; Desnick
- Page 377 and 378:
Zhou, J.; Xu, Y.-H.; Chang, H.-F. (
- Page 379 and 380:
Air Quality Criteria for Lead Volum
- Page 381 and 382:
The purpose of this revised Lead AQ
- Page 383 and 384:
Air Quality Criteria for Lead (Seco
- Page 385 and 386:
List of Tables Number Page AX6-2.1
- Page 387 and 388:
List of Tables (cont’d) Number Pa
- Page 389 and 390:
Principal Authors Authors, Contribu
- Page 391 and 392:
Principal Authors Authors, Contribu
- Page 393 and 394:
Principle Authors (cont’d) Author
- Page 395 and 396:
Technical Support Staff U.S. Enviro
- Page 397 and 398:
Members (cont’d) U.S. Environment
- Page 399 and 400:
ANOVA analysis of variance ANP atri
- Page 401 and 402:
CCD charge-coupled device CCE Coord
- Page 403 and 404:
DPPD N-N-diphenyl-p-phynylene-diami
- Page 405 and 406:
FTES free testosterone FTII Fagan T
- Page 407 and 408:
HPLC high-pressure liquid chromatog
- Page 409 and 410:
MAO monoamine oxidase MATC maximum
- Page 411 and 412:
NORs nucleolar organizing regions N
- Page 413 and 414:
ppm parts per million PPVT-R Peabod
- Page 415 and 416:
SOPR sperm-oocyte penetration rate
- Page 417 and 418:
vit C vitamin C vit E vitamin E VMA
- Page 419 and 420:
ANNEX TABLES AX6-2 AX6-2
- Page 421 and 422:
AX6-4 Table AX6-2.1 (cont’d). Pro
- Page 423 and 424:
AX6-6 Table AX6-2.1 (cont’d). Pro
- Page 425 and 426:
AX6-8 Table AX6-2.1 (cont’d). Pro
- Page 427 and 428:
AX6-10 Table AX6-2.2 (cont’d). Me
- Page 429 and 430:
AX6-12 Table AX6-2.3 (cont’d). Cr
- Page 431 and 432:
AX6-14 Table AX6-2.4. Effects of Le
- Page 433 and 434:
AX6-16 Table AX6-2.4 (cont’d). Ef
- Page 435 and 436:
AX6-18 Table AX6-2.5 (cont’d). Ef
- Page 437 and 438:
AX6-20 Table AX6-2.6 (cont’d). Ef
- Page 439 and 440:
AX6-22 Table AX6-2.6 (cont’d). Ef
- Page 441 and 442:
AX6-24 Table AX6-2.8. Effects of Le
- Page 443 and 444:
AX6-26 Table AX6-2.9 (cont’d). Ef
- Page 445 and 446:
AX6-28 Table AX6-2.10 (cont’d). R
- Page 447 and 448:
AX6-30 Table AX6-3.1. Neurobehavior
- Page 449 and 450:
AX6-32 Table AX6-3.1 (cont’d). Ne
- Page 451 and 452:
AX6-34 Table AX6-3.2 (cont’d). Sy
- Page 453 and 454:
AX6-36 Table AX6-3.3. Neurobehavior
- Page 455 and 456:
AX6-38 Table AX6-3.3 (cont’d). Ne
- Page 457 and 458:
AX6-40 Table AX6-3.3 (cont’d). Ne
- Page 459 and 460:
AX6-42 Table AX6-3.3 (cont’d). Ne
- Page 461 and 462:
AX6-44 Table AX6-3.3 (cont’d). Ne
- Page 463 and 464:
AX6-46 Table AX6-3.3 (cont’d). Ne
- Page 465 and 466:
AX6-48 Table AX6-3.3 (cont’d). Ne
- Page 467 and 468:
AX6-50 Table AX6-3.4 (cont’d). Me
- Page 469 and 470:
AX6-52 Table AX6-3.5 (cont’d). Ne
- Page 471 and 472:
AX6-54 Table AX6-3.5 (cont’d). Ne
- Page 473 and 474:
AX6-56 Table AX6-3.6. Evoked Potent
- Page 475 and 476:
AX6-58 Table AX6-3.6 (cont’d). Ev
- Page 477 and 478:
AX6-60 Table AX6-3.7 (cont’d). Po
- Page 479 and 480:
AX6-62 Table AX6-3.7 (cont’d). Po
- Page 481 and 482:
AX6-64 Table AX6-3.8 (cont’d). Oc
- Page 483 and 484:
AX6-66 Table AX6-3.9. Other Neurolo
- Page 485 and 486:
AX6-68 Table AX6-3.9 (cont’d). Ot
- Page 487 and 488:
AX6-70 Table AX6-4.1. Renal Effects
- Page 489 and 490:
AX6-72 Table AX6-4.1 (cont’d). Re
- Page 491 and 492:
AX6-74 Table AX6-4.1 (cont’d). Re
- Page 493 and 494:
AX6-76 Table AX6-4.1 (cont’d). Re
- Page 495 and 496:
AX6-78 Table AX6-4.1 (cont’d). Re
- Page 497 and 498:
AX6-80 Table AX6-4.1 (cont’d). Re
- Page 499 and 500:
AX6-82 Table AX6-4.2 (cont’d). Re
- Page 501 and 502:
AX6-84 Table AX6-4.2 (cont’d). Re
- Page 503 and 504:
AX6-86 Table AX6-4.2 (cont’d). Re
- Page 505 and 506:
AX6-88 Table AX6-4.2 (cont’d). Re
- Page 507 and 508:
AX6-90 Table AX6-4.2 (cont’d). Re
- Page 509 and 510:
AX6-92 Table AX6-4.2 (cont’d). Re
- Page 511 and 512:
AX6-94 Table AX6-4.2 (cont’d). Re
- Page 513 and 514:
AX6-96 Table AX6-4.2 (cont’d). Re
- Page 515 and 516:
AX6-98 Table AX6-4.2 (cont’d). Re
- Page 517 and 518:
AX6-100 Table AX6-4.2 (cont’d). R
- Page 519 and 520:
AX6-102 Table AX6-4.2 (cont’d). R
- Page 521 and 522:
AX6-104 Table AX6-4.3. Renal Effect
- Page 523 and 524:
AX6-106 Table AX6-4.3 (cont’d). R
- Page 525 and 526:
AX6-108 Table AX6-4.3 (cont’d). R
- Page 527 and 528:
AX6-110 Table AX6-4.3 (cont’d). R
- Page 529 and 530:
AX6-112 Table AX6-4.3 (cont’d). R
- Page 531 and 532:
AX6-114 Table AX6-4.3 (cont’d). R
- Page 533 and 534:
AX6-116 Table AX6-4.3 (cont’d). R
- Page 535 and 536:
AX6-118 Table AX6-4.3 (cont’d). R
- Page 537 and 538:
AX6-120 Table AX6-4.4. Renal Effect
- Page 539 and 540:
AX6-122 Table AX6-4.5. Renal Effect
- Page 541 and 542:
AX6-124 Table AX6-4.5 (cont’d). R
- Page 543 and 544:
AX6-126 Table AX6-4.5 (cont’d). R
- Page 545 and 546:
AX6-128 Table AX6-4.5 (cont’d). R
- Page 547 and 548:
AX6-130 Table AX6-5.1. Effects of L
- Page 549 and 550:
AX6-132 Table AX6-5.1 (cont’d). E
- Page 551 and 552:
AX6-134 Table AX6-5.1 (cont’d). E
- Page 553 and 554:
AX6-136 Table AX6-5.1 (cont’d). E
- Page 555 and 556:
AX6-138 Table AX6-5.1 (cont’d). E
- Page 557 and 558:
AX6-140 Table AX6-5.1 (cont’d). E
- Page 559 and 560:
AX6-142 Table AX6-5.1 (cont’d). E
- Page 561 and 562:
AX6-144 Table AX6-5.1 (cont’d). E
- Page 563 and 564:
AX6-146 Table AX6-5.1 (cont’d). E
- Page 565 and 566:
AX6-148 Table AX6-5.1 (cont’d). E
- Page 567 and 568:
AX6-150 Table AX6-5.1 (cont’d). E
- Page 569 and 570:
AX6-152 Table AX6-5.1 (cont’d). E
- Page 571 and 572:
AX6-154 Table AX6-5.1 (cont’d). E
- Page 573 and 574:
AX6-156 Table AX6-5.1 (cont’d). E
- Page 575 and 576:
AX6-158 Table AX6-5.1 (cont’d). E
- Page 577 and 578:
AX6-160 Table AX6-5.2 (cont’d). E
- Page 579 and 580:
AX6-162 Table AX6-5.3. Effects of L
- Page 581 and 582:
AX6-164 Table AX6-5.3 (cont’d). E
- Page 583 and 584:
AX6-166 Table AX6-5.4. Cardiovascul
- Page 585 and 586:
ANNEX TABLES AX6-6 AX6-168
- Page 587 and 588:
AX6-170 Table AX6-6.1 (cont’d). P
- Page 589 and 590:
AX172 Table AX6-6.1 (cont’d). Pla
- Page 591 and 592:
AX6-174 Table AX6-6.2. Lead Exposur
- Page 593 and 594:
AX6-176 Table AX6-6.2 (cont’d). L
- Page 595 and 596:
AX6-178 Table AX6-6.3. Lead Exposur
- Page 597 and 598:
AX6-180 Table AX6-6.4. Lead Exposur
- Page 599 and 600:
ANNEX TABLES AX6-7 AX6-182
- Page 601 and 602:
AX6-184 Table AX6-7.1 (cont’d). R
- Page 603 and 604:
AX6-186 Table AX6-7.2. Key Occupati
- Page 605 and 606:
AX6-188 Table AX6-7.2 (cont’d). K
- Page 607 and 608:
AX6-190 Table AX6-7.2 (cont’d). K
- Page 609 and 610:
AX6-192 Table AX6-7.3. Key Studies
- Page 611 and 612:
AX6-194 Table AX6-7.4. Other Studie
- Page 613 and 614:
AX6-196 Table AX6-7.4 (cont’d). O
- Page 615 and 616:
AX6-198 Table AX6-7.4 (cont’d). O
- Page 617 and 618:
AX6-200 Table AX6-7.4 (cont’d). O
- Page 619 and 620:
AX6-202 Table AX6-7.4 (cont’d). O
- Page 621 and 622:
AX6-204 Table AX6-7.4 (cont’d). O
- Page 623 and 624:
ANNEX TABLES AX6-8 AX6-206
- Page 625 and 626:
AX6-208 Table AX6-8.1 (cont’d). E
- Page 627 and 628:
AX6-210 Table AX6-8.1 (cont’d). E
- Page 629 and 630:
AX6-212 Table AX6-8.2 (cont’d). E
- Page 631 and 632:
AX6-214 Table AX6-8.2 (cont’d). E
- Page 633 and 634:
AX6-216 Table AX6-8.2 (cont’d). E
- Page 635 and 636:
AX6-218 Table AX6-8.2 (cont’d). E
- Page 637 and 638:
ANNEX TABLES AX6-9 AX6-220
- Page 639 and 640:
AX6-222 Table AX6-9.1 (cont’d). E
- Page 641 and 642:
AX6-224 Table 6-9.2 (cont’d). Eff
- Page 643 and 644:
AX6-226 Table 6-9.2 (cont’d). Eff
- Page 645 and 646:
AX6-228 Table 6-9.2 (cont’d). Eff
- Page 647 and 648:
AX6-230 Table 6-9.2 (cont’d). Eff
- Page 649 and 650:
AX6-232 Table AX6-9.3 (cont’d.).
- Page 651 and 652:
AX6-234 Table AX6-9.4. Effects of L
- Page 653 and 654:
AX6-236 Table AX6-9.4 (cont’d). E
- Page 655 and 656:
AX6-238 Table AX6-9.4 (cont’d). E
- Page 657 and 658:
AX6-240 Table AX6-9.4 (cont’d). E
- Page 659 and 660:
AX6-242 Table AX6-9.5 (cont’d). E
- Page 661 and 662:
AX6-244 Table AX6-9.6 (cont’d). E
- Page 663 and 664:
AX6-246 Table AX6-9.6 (cont’d). E
- Page 665 and 666:
AX6-248 Table AX6-9.6 (cont’d). E
- Page 667 and 668:
AX6-250 Table AX6-9.6 (cont’d). E
- Page 669 and 670:
AX6-252 Table AX6-9.7 (cont’d). E
- Page 671 and 672:
AX6-254 Table AX6-9.8 (cont’d). E
- Page 673 and 674:
AX6-256 Table AX6-9.9 (cont’d). E
- Page 675 and 676:
AX6-258 Table AX6-9.10. Effects of
- Page 677 and 678:
REFERENCES Abbate, C.; Buceti, R.;
- Page 679 and 680:
Baghurst, P. A.; McMichael, A. J.;
- Page 681 and 682:
Bolla, K. I.; Schwartz, B. S.; Stew
- Page 683 and 684:
Chia, K. S.; Jeyaratnam, J.; Tan, C
- Page 685 and 686:
David, O. J.; Clark, J.; Hoffman, S
- Page 687 and 688:
Englyst, V.; Lundstrom, N. G.; Gerh
- Page 689 and 690:
Gennart, J. P.; Bernard, A.; Lauwer
- Page 691 and 692:
Haraguchi, T.; Ishizu, H.; Takehisa
- Page 693 and 694:
Jemal, A.; Graubard, B. I.; Devesa,
- Page 695 and 696:
Lanphear, B. P.; Howard, C.; Eberly
- Page 697 and 698:
Lundström, N.-G.; Nordberg, G.; En
- Page 699 and 700:
Muntner, P.; He, J.; Vupputuri, S.;
- Page 701 and 702:
Paksy, K.; Gáti, I.; Náray, M.; R
- Page 703 and 704:
Rhainds, M.; Levallois, P.; Dewaill
- Page 705 and 706:
Sargent, J. D.; Dalton, M. A.; O'Co
- Page 707 and 708:
Sheffet, A.; Thind, I.; Miller, A.
- Page 709 and 710:
Stevens, L. A.; Levey, A. S. (2005b
- Page 711 and 712:
Van Larebeke, N.; Koppen, G.; Nelen
- Page 713 and 714:
Winker, R.; Ponocny-Seliger, E.; R
- Page 715 and 716:
October 2006 EPA/600/R-05/144bF Air
- Page 717 and 718:
PREFACE National Ambient Air Qualit
- Page 719 and 720:
drafts of document materials were r
- Page 721 and 722:
Table of Contents PREFACE..........
- Page 723 and 724:
Table of Contents (cont’d) II-ix
- Page 725 and 726:
List of Tables (cont’d) AX7-2.3.1
- Page 727 and 728:
List of Figures (cont’d) Number P
- Page 729 and 730:
Principal Authors Authors, Contribu
- Page 731 and 732:
Principal Authors Authors, Contribu
- Page 733 and 734:
Principle Authors (cont’d) Author
- Page 735 and 736:
Technical Support Staff U.S. Enviro
- Page 737 and 738:
Members (cont’d) U.S. Environment
- Page 739 and 740:
ANOVA analysis of variance ANP atri
- Page 741 and 742:
CCD charge-coupled device CCE Coord
- Page 743 and 744:
DPPD N-N-diphenyl-p-phynylene-diami
- Page 745 and 746:
FTES free testosterone FTII Fagan T
- Page 747 and 748:
HPLC high-pressure liquid chromatog
- Page 749 and 750:
MAO monoamine oxidase MATC maximum
- Page 751 and 752:
NORs nucleolar organizing regions N
- Page 753 and 754:
ppm parts per million PPVT-R Peabod
- Page 755 and 756:
SOPR sperm-oocyte penetration rate
- Page 757 and 758:
vit C vitamin C vit E vitamin E VMA
- Page 759 and 760:
Pb is ideally suited for this task.
- Page 761 and 762:
Concept For a given metal or metall
- Page 763 and 764:
(1979) observed that “the smaller
- Page 765 and 766:
Figure AX7-1.1.3. Illustration of p
- Page 767 and 768:
• Colorimetric • Electrochemica
- Page 769 and 770:
Figure AX7-1.1.5. Bulk lead versus
- Page 771 and 772:
diffraction lines and comparing the
- Page 773 and 774:
The major disadvantage of SIMS to s
- Page 775 and 776:
techniques can be useful in a study
- Page 777 and 778:
have included phosphoric acid (H3PO
- Page 779 and 780:
to 15 years after biosolid applicat
- Page 781 and 782:
thin films (DGT), and ICP technique
- Page 783 and 784:
completely extract targeted phases.
- Page 785 and 786:
epresents Eb. The precise energy re
- Page 787 and 788:
1974; Ruby et al., 1994). However,
- Page 789 and 790:
T1/2 = 14 × 10 9 year). The result
- Page 791 and 792:
floor) time-series data to evaluate
- Page 793 and 794:
contributions of dry deposition may
- Page 795 and 796:
Compared to their estimated 20th-ce
- Page 797 and 798:
thought to enter the plant via the
- Page 799 and 800:
soil was not allowed to equilibrate
- Page 801 and 802:
Lead concentrations in various tiss
- Page 803 and 804:
that the nematode may detoxify Pb v
- Page 805 and 806:
plasma levels of uric acid and crea
- Page 807 and 808:
effective use of glutathione metabo
- Page 809 and 810:
and oats (Avena sativa) had signifi
- Page 811 and 812:
other metals is inconsistent (Påhl
- Page 813 and 814:
Speciation and Form of Lead Recent
- Page 815 and 816:
organism responses to Pb. Section A
- Page 817 and 818:
Primary Producers Commonly reported
- Page 819 and 820:
solution and minimal translocation
- Page 821 and 822:
AX7.1.3.3 Recent Studies on the Eff
- Page 823 and 824:
AX7-66 Avian Species Reproduction J
- Page 825 and 826:
AX7-68 Avian Species American kestr
- Page 827 and 828:
Very little research has been done
- Page 829 and 830:
AX7-72 Mammalian Species Reproducti
- Page 831 and 832:
AX7-74 Mammalian Species No. of Dos
- Page 833 and 834:
AX7-76 Mammalian Species No. of Dos
- Page 835 and 836:
AX7-78 Mammalian Species No. of Dos
- Page 837 and 838:
AX7-80 Mammalia n Species No. of Do
- Page 839 and 840:
A literature search and review was
- Page 841 and 842:
Table AX7-1.3.6. Invertebrate Toxic
- Page 843 and 844:
The effects of Pb-chloride on the p
- Page 845 and 846:
Ecological Soil Screening Levels (E
- Page 847 and 848:
Since the movement and fate of Pb i
- Page 849 and 850:
Land Use and Industry Changes in la
- Page 851 and 852:
lakes in the United Kingdom the dis
- Page 853 and 854:
zinc; had very low pH; and were det
- Page 855 and 856:
Sites Affected by Long-Range Lead T
- Page 857 and 858:
iomass carbon. Because of this link
- Page 859 and 860:
in an oak woodland site 3 km from a
- Page 861 and 862:
the forested Lehstenbach catchment
- Page 863 and 864:
there is little evidence that Pb ac
- Page 865 and 866:
ecosystems. Just as in the terrestr
- Page 867 and 868:
To develop chronic AWQC, acceptable
- Page 869 and 870:
for the binding of free-metal ion a
- Page 871 and 872:
partition in sediment between acid-
- Page 873 and 874:
AX7.2.1.5 Metal Mixtures As discuss
- Page 875 and 876:
varies from 4:1 in rural streams to
- Page 877 and 878:
Organic compounds in surface waters
- Page 879 and 880:
solution phase, complexation with c
- Page 881 and 882:
The NAWQA dataset was chosen over o
- Page 883 and 884:
Lead Distributions Generated from t
- Page 885 and 886:
AX7-128 Figure AX7-2.2.3. Spatial d
- Page 887 and 888:
AX7-130 Figure AX7-2.2.5. Spatial d
- Page 889 and 890:
AX7-132 ` Figure AX7-2.2.7. Spatial
- Page 891 and 892:
Figure AX7-2.2.8. Frequency distrib
- Page 893 and 894:
Table AX7-2.2.4. Summary Statistics
- Page 895 and 896:
Table AX7-2.2.5. Comparison of NCBP
- Page 897 and 898:
AX7-140 Figure AX7-2.2.13. Spatial
- Page 899 and 900:
calculations indicate that only a s
- Page 901 and 902:
from municipal sewage, storm runoff
- Page 903 and 904:
AX7.2.3 Aquatic Species Response/Mo
- Page 905 and 906:
aquatic plants and insects and on t
- Page 907 and 908:
designed to model uptake, MINTEQ pr
- Page 909 and 910:
sequestering to organ tissues). The
- Page 911 and 912:
AbdAllah and Moustafa (2002) studie
- Page 913 and 914:
Summary of Detoxifiction Processes
- Page 915 and 916:
1.1 µg/L Cd, 12 µg/L Cu, 55 µg/L
- Page 917 and 918:
Studies have identified ALAD in fis
- Page 919 and 920:
metals over nonessential metals. Th
- Page 921 and 922:
In summary, relationships between a
- Page 923 and 924:
potential toxic effects in other or
- Page 925 and 926:
esulted in 91.7% survival (Horne an
- Page 927 and 928:
carbon sources (including glucose),
- Page 929 and 930:
separate concentration-effects mode
- Page 931 and 932:
1994. mSQGQs are useful to risk ass
- Page 933 and 934:
Algae The 1986 Lead AQCD (U.S. Envi
- Page 935 and 936:
observed in Selenastrum capricornut
- Page 937 and 938:
Nitrate uptake reported after 48, 7
- Page 939 and 940:
1997). The most sensitive primary p
- Page 941 and 942:
Freshwater Invertebrates Acute and
- Page 943 and 944:
AX7-186 Amphipod (Hyalella azteca)
- Page 945 and 946:
concentrations of
- Page 947 and 948:
AX7-190 Freshwater Species Chemical
- Page 949 and 950:
AX7-192 Species Chemical Frogs (Ran
- Page 951 and 952:
studied using Spirodela polyrhiza,
- Page 953 and 954:
However, in other cases multivariat
- Page 955 and 956:
species was observed. Similar, sign
- Page 957 and 958:
AX7-200 Table AX7-2.5.2. Essential
- Page 959 and 960:
AX7-202 Table AX7-2.5.2 (cont’d).
- Page 961 and 962:
variables, it does not imply causat
- Page 963 and 964:
Poulton et al. (1995), the effects
- Page 965 and 966:
metal levels. Furthermore, although
- Page 967 and 968:
environment through bioaccumulation
- Page 969 and 970:
Angle, C. R.; McIntire, M. S.; Colu
- Page 971 and 972:
Black, M. C.; Ferrell, J. R.; Horni
- Page 973 and 974:
Clements, W. H. (1994) Benthic inve
- Page 975 and 976:
Ekenler, M.; Tabatabai, M. (2002) E
- Page 977 and 978:
Getz, L. L.; Haney, A. W.; Larimore
- Page 979 and 980:
Houlton, B. Z.; Driscoll, C. T.; Fa
- Page 981 and 982:
Krüger, F.; Gröngröft, A. (2003)
- Page 983 and 984:
Manceau, A.; Lanson, B.; Schlegel,
- Page 985 and 986:
Niyogi, S.; Wood, C. M. (2003) Effe
- Page 987 and 988:
Rand, G. M.; Wells, P. G.; McCarty,
- Page 989 and 990:
Scherer, E.; McNicol, R. E. (1998)
- Page 991 and 992:
Sturges, W. T.; Barrie, L. A. (1987
- Page 993 and 994:
U.S. Environmental Protection Agenc
- Page 995 and 996:
Zenk, M. H. (1996) Heavy metal deto
Inappropriate
Loading...
Inappropriate
You have already flagged this document.
Thank you, for helping us keep this platform clean.
The editors will have a look at it as soon as possible.
Mail this publication
Loading...
Embed
Loading...
Delete template?
Are you sure you want to delete your template?
DOWNLOAD ePAPER
This ePaper is currently not available for download.
You can find similar magazines on this topic below under ‘Recommendations’.